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Undernutrition occurs when the amount of micronutrients and macronutri-ents derived from food is inadequate to meet the body’s daily nutritional requirement and to maintain optimum bodily functions (Manary and San-
dige, 2008). Low- and middle-income countries have the highest prevalence rates of 
childhood undernutrition (Bhutta et al., 2013). More than 155 million children are 
stunted (<-2SD from median height for age of reference population) and 50 million 
suffer from wasting (<-2SD from median weight for height of reference population) 
in the world (UNICEF, WHO, Group WB, 2015). Wasting can be subdivided into 
Severe Acute Malnutrition (SAM; defi ned as <-3SD from median weight for height 
of reference population, or MUAC <115mm without presence of bilateral oedema), 
which accounts for 16 million cases of the total 50 million, and Moderate Acute 
Malnutrition (MAM; defi ned as <-2SD but >-3SD from median weight for height of 
reference population, or MUAC between 115mm and 125 mm without presence 
of bilateral oedema). Undernutrition is associated with around 45–50% of deaths in 
children younger than 5 years, which is approximately 2.5 million childhood deaths 
annually (Bhutta et al., 2013; UNICEF, WHO, Group WB, 2015). Malnutrition impairs 
cognitive function, reducing productivity and economic growth (Martins et al., 2011). 
It is estimated that undernutrition reduces economic development by 8% (Hor-
ton and Lo, 2013). Interventions prevent undernutrition, hence improving economic 
growth (Hoddinott et al., 2008).
Lipid-based nutrient supplements (LNS) are pre-packaged, in a semi-solid paste, 
containing essential macro- and micronutrients, including minerals, fatty acids, pro-
teins, milk, sugar and peanuts (Chaparro and Dewey, 2010; Nutriset, n.d.; Arimond 
et al., 2015; Talley et al., 2012). Their low moisture content helps to ensure food 
safety, by discouraging bacterial growth. This reduces the risk of diarrhoea infections, 
a major cause of childhood morbidity and mortality (UNICEF, WHO, Group WB, 
2015; Schoonees et al., 2013). There are numerous variants of LNS, such as fortifi ed 
spreads (FS), ready-to-use supplementary foods (RUSF), ready-to-use foods (RUF), 
ready-to-use therapeutic food (RUTF), ready-to-use complementary food (RUCF) 
and energy-dense complementary food (Nutriset, n.d.; Arimond et al., 2015). These 
preparations have enabled more children to be treated at home, through the Com-
munity Management of Malnutrition (CMAM). The most commonly used variant 
of LNS, RUTF (PlumpyNut®), has been successfully used in the treatment of SAM 
in more than 50 countries, with more than 3 million cases being treated annually 
(UNICEF, WHO, Group WB, 2015). SAM children require a higher dose of plumpy 
nut (200–300g/day) to provide 200kcal of energy daily, compared with lower doses 
of other LNS products (20–50g/day), which supply about 100–250 kcal/day (Chapar-
ro and Dewey, 2010). LNS should not be seen as a substitute for breast milk, which 
provides essential nutrients for infants (Bhutta et al., 2013; Briend and Collins, 2010; 
Owino et al., 2011).
Previous experimental studies showed that LNS are benefi cial in improving
anthropometric status in children (Talley et al., 2012; Lin et al., 2008; Isanaka
et al., 2009; Isanaka et al., 2010; Mangani et al., 2013; Matilsky et al., 2009). However, 
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there were discrepancies in the results of certain outcomes, such as in Mangani
et al. (2013). LNS did not improve linear growth and in Bismwa et al. 2012), LNS had 
no effect on stunting, or weight gain, amongst Congolese infants. Such disparities may 
be due to the varied duration of interventions (Simondon et al., 1996) and existing 
co-morbidities. Some nutrition stakeholders are unsure about the role of these
products. Clear recommendations have not been issued for the utilisation of these 
products, to prevent undernutrition. The human and economic cost of malnutrition 
calls for an effective strategy to prevent the onset of undernutrition and halt the
progression of MAM to SAM (Manary and Sandige, 2008; Chaparro and Dewey, 2010).
The 2008 and 2013 Lancet nutrition series support the prioritisation of preventing
undernutrition, as a key strategy in achieving global nutrition targets (Victoria
et al., 2008). The United Kingdom’s Department for International Development’s
(DFID) review of prevention activities highlighted the lack of robust evidence, 
supporting the continued use of ineffective interventions to prevent undernutri-
tion. LNS products could help close the gap until underlying causes are addressed
(Coffey, 2016).
To the best of the authors’ knowledge, no systematic review, on the use of LNS for 
prevention and treatment of childhood malnutrition, has been conducted. There are 
two recent reviews, but both are focused on specifi c forms of LNS. A previous Co-
chrane review focused on RUTF for treating SAM (Schoonees et al., 2013) as well as 
a review by Lenters et al. (2013) focused on RUSF and RUTF for treating MAM and 
SAM. Previous reviews were limited, due to the inclusion of a few studies with the 
same variant of LNS. Included studies had high dropout rates, small sample sizes, and 
were conducted by the same authors in the same locations, affecting the generalis-
ability of the results (Pope et al., 2007). This systematic review focuses on preven-
tion and treatment of undernutrition, in particular, moderate undernutrition, with 
the use of all variants of LNS. This study can provide evidence to support resource 
allocation by countries and humanitarian organisations coping with the challenges of 
malnutrition. The systematic review includes a meta-analysis, to analyse the impact 
of LNS on prevention and treatment of undernutrition, in under -5s, by exploring 
changes in anthropometry, in those with wasting, underweight and stunting, as well 
as recovery from MAM. The meta-analysis also aims at assessing the effectiveness of 
LNS for prevention and/or treatment of MAM as compared with control (habitual 
diet) and/or corn soy blend (CSB). It further intends to compare whether milk-
based LNS and soy-based LNS have different effectiveness as compared with each 
other or with CSB.
METHODS
This systematic review was written according to the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Moher et al., 2009 ), 
and the research protocol was registered on the University of York’s PROSPERO 
database (CRD42015025019) for systematic reviews and meta-analysis.
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Types of studies
All randomised control trials (RCT), quasi-ran-
domised trials (trials that lacked adequacy of 
randomisation, such as alternation of study par-
ticipants) and cluster-randomised trials (trials 
randomised by villages and health care centres) 
for treating and/or preventing MAM (Moderate 
Acute Malnutrition) as well as chronic malnutrition 
(stunting) were included.
Types of participants
Trials with children aged between 6 months and 
5 years identifi ed as normal, underweight, stunted, 
wasted or with MAM were included, irrespective 
of the country and study setting. MAM, also known 
as moderate wasting, is defi ned by a weight for 
height indicator between -3 and -2 z-scores (stan-
dard deviations) of the international standard or 
by a mid-upper arm circumference (MUAC) be-
tween 11 cm and 12.5 cm with no oedema. Stunt-
ing and underweight are defi ned by height for age 
and weight for age indicators below -2z-scores 
from median of reference population, respectively 
(UNICEF, WHO, Group WB, 2015).
Types of interventions
For the experimental group, we included data 
from studies with lipid-based nutrient supplements 
(LNS) regardless of type and source (soy-based 
or milk-based, locally or commercially produced). 
The control group included data from children not
receiving LNS supplements or who were on
habitual diet. Interventions such as corn soybean 
(CSB), also known as improved dry ration (IDR) 
or Likuli Phala, were classifi ed as the non-LNS
supplementation group to form another
comparison arm. Likuli Phala is a mixture of 
corn and soya bean fortifi ed with micronu-
trients (Matilsky et al., 2009). Trials that made
comparisons only between variants of LNS or 
combined another form of management with LNS 
such as sprinkles, zinc, iron, micronutrient powder 
and those solely on acceptability of LNS were not 
included in this review. Studies on the management 
of SAM and MAM with use of products other than 
LNS were excluded.
Data was classifi ed into fi ve comparison groups: 1) 
LNS (milk- or soy-based) versus Control (habitu-
al diet); 2) LNS (milk-based) versus CSB; 3) LNS 
(soy-based) versus CSB; 4) LNS (milk-based) ver-
sus LNS (soy-based); and 5) LNS versus Control 
and/or CSB. For comparison group 1, due to miss-
ing information on whether LNS (in the included 
studies) was milk- or soy-based, we could not 
split comparison 1 into milk-based and soy-based 
groups. Comparison group 5 drew data from com-
parisons 1, 2 and 3 to provide a summarised effect 
of LNS on undernutrition, and this was performed 
only for the primary outcomes.
Types of outcomes
To be eligible, studies must include data from at 
least one primary outcome of interest, which 
included: mean change in height/length for age 
z-scores (HAZ), mean change in weight for age 
z-scores (WAZ), mean change in weight for height/
length z-scores (WHZ) and recovery from MAM. 
The secondary outcomes were as follows: mean 
change in mid-upper arm circumference (MUAC), 
mean weight gain in kg and mean height/length gain 
in cm. Occurrence of diarrhoea, fever and cough 
during the intervention were also included as sec-
ondary outcomes. Cases of allergies to peanut 
were considered as adverse effects of the inter-
vention.
Methods of search for identifi cation of 
studies
The following electronic databases were searched 
from inception (up to 2017) to identify relevant 
studies for this review:
  The Cochrane central register of clinical trials 
(CENTRAL)
The Medline - 1946
EMBASE – from 1980
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Clinicaltrials.Gov
CINAHL - 1947
WHO international clinical trials registry plat-
form
In addition, references of selected trials were hand 
searched. Similarly, grey literature and relevant 
websites such as those of CMAM Forum, Emer-
gency Nutrition Network, Epicentre and World 
Bank were searched. All international organisations 
using LNS as well as authors of trials in the trial 
register were contacted through standard emails 
requesting information about ongoing research 
and unpublished trials. Only one organisation re-
sponded to having an ongoing trial. There was no 
reply from other organisations or authors, despite 
establishing contact through reminder emails at 
2-week intervals (total of 6 weeks). Hence, this 
review was solely based on primarily published 
studies.
Relevant studies were included, regardless of the 
language and status of publication (published, un-
published or ongoing) and the date of publication 
or the date when the study was conducted. Two 
independent reviewers selected the papers for in-
clusion. The title and abstract of each study iden-
tifi ed through the search strategy were carefully 
screened by OTR and ARAA while being guided by 
the pre-specifi ed eligibility criteria, to select rele-
vant papers. The full text of any study considered 
to be eligible after reading the abstract was ob-
tained.
Data extraction
Data were extracted systematically by using a 
specially designed and pre-piloted data extraction 
form. For every relevant study, the following infor-
mation was extracted: source (e.g. study identifi ca-
tion, citation and contact details), eligibility criteria, 
methods (e.g. study design, total duration, blinding), 
characteristics of participants (e.g. sample size, age, 
setting and sex), interventions (e.g. type, dose and 
duration), outcome (e.g. outcome description, unit 
and time points), results for each outcome, safety 
issues, funding and conclusions. The extracted data 
were enlisted into either characteristics of includ-
ed studies or characteristics of excluded studies 
or characteristics of ongoing studies.
To identify instances of multiple publications from 
the study, information about characteristics of 
the participants, type of intervention, period and 
place of study from all the papers were extracted. 
In addition, the primary reviewer (OTR) tried to 
contact the trial authors to confi rm whether the 
articles reported results of the same study. In the 
case of multiple publications, the most complete 
articles were considered, such as those including 
a greater number of outcomes and more method-
ological information, as primary references.
Quality appraisal
Each study included in this review was assessed for 
the risk of bias by using the Cochrane risk of bias 
tool (Higgins, 2011). The potential sources of bias-
es assessed in the studies were: random sequence 
generation, allocation concealment, blinding, attri-
tion, selective reporting and other bias such as the 
source of funding and compliance. Each of these 
domains were rated as high risk of bias, low risk 
of bias or unclear risk of bias when information 
was not clearly provided in the text. For attrition 
bias, each study was represented: as high risk if 
more than 20% were lost to follow-up or if loss 
to follow-up was more than allowed for the study, 
as low risk if less than 20% or less than the rate 
allowed for that particular study and unclear when 
information was not clearly stated. Cluster-ran-
domised trials were further assessed for recruit-
ment bias, missing clusters and discrepancies in 
baseline characteristics.
Data analysis
Where insuffi cient or incomplete data were
reported in a paper, the corresponding au-
thor was contacted. The extracted data were 
entered into both Revman and STATA (ver-
sion 12.0, StataCorp, College Station, Tex-
as, USA) for the analysis. Meta-analyses were 
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conducted when a group of studies was suffi -
ciently homogeneous in terms of participants,
interventions and outcomes to provide a mean-
ingful summary. However, it is acknowledged “a 
priori” due to the diverse nature of interven-
tion type, in terms of duration, intensity, settings 
and type of participants. Therefore, statistical
heterogeneity seemed inevitable and random-ef-
fects models were applied when appropriate.
The summary estimates for continuous data 
were calculated by using weighted mean
difference (WMD) based on changes from
baseline to post-intervention using the generic in-
versevariance and expressed with the random-ef-
fects model. Dichotomous data were calculated by 
risk ratio (RR) and expressed with random effect 
(DerSimonian and Laird, 1986). All results were 
presented with 95% confi dence interval (CI) and 
represented on a forest plot, and the null hypothe-
sis of no effect was rejected at P ≤ 0.05.
For cluster-randomised trials, we followed the 
method of adjusting for clustering as described in 
the Cochrane Handbook for Systematic Reviews 
of Interventions (Higgins and Green, 2011). The 
data were adjusted by the design effect using the 
following formulae: 1 + (M [average cluster size] 
– 1) ICC [intra-cluster correlation coeffi cient]. 
Whenever the ICC was not reported in the study, 
a low ICC of 0.001 (based on previous literature 
[Schoonees et al., 2013; Huybregts et al., 2012]) 
was imputed because we did not anticipate large 
between-cluster variability. For dichotomous
outcomes, both the number of participants and
the number who experienced the event were
divided by the same design effect; however, for 
continuous outcomes, only the sample size was re-
duced (means and SDs were left unchanged).
When studies with continuous outcomes did 
not report required standard deviations to allow 
for meta-analysis, other reported measures of
dispersion (e.g. confi dence intervals, standard
errors, P values) were used to approximate the 
missing values (standard deviation) by using the 
formulas described in Higgins (2011). This was also 
used to derive the changes in outcome variables 
for studies that only provided the baseline and 
end-of-intervention measures.
Three studies (Mangani et al., 2013; Matilsky
et al., 2009; LaGrone et al., 2011) had two treat-
ment groups of LNS compared with CSB data: 
One experimental arm had milk-based LNS, and 
the other had soy-based LNS. However, as these 
two experimental arms can form three kinds of 
research questions, they were analysed separately 
(Higgins and Green, 2011): LNS (milk-based) ver-
sus CSB; LNS (soy-based) versus CSB; and LNS 
(milk-based) versus LNS (soy-based). Similarly, this 
strategy was applied to Thakwalakwa et al. (2010), 
Thakwalakwa et al. (2012) (29) and Mangani et al. 
(2013) (17), which included a control group (ha-
bitual diet), apart from CSB and LNS experimental 
arms. Since there were no substantial distinctions 
of the types of fortifi ed spreads (FS50, FS25 and 
others) used in some studies (Lin et al., 2008; Phu-
ka et al., 2009a), data from studies that used two or 
more types of fortifi ed spreads (Phuka et al., 2008; 
Kuusipalo et al., 2006) were merged together and 
compared with the CSB.
For the comparison group 5 (LNS versus Control 
and/or CSB), data were drawn from comparison 
groups 1, 2 and 3 (LNS versus control/habitual diet, 
LNS milk-based versus CSB, LNS soy-based versus 
CSB respectively). We collated the data from each 
study and analysed them with Revman to generate 
a single forest plot. For dichotomous outcomes, 
both the number of events and the total number 
of participants were divided. For continuous out-
comes, only the total number of participants were 
divided and the means and standard deviations 
were left unchanged. This analysis was performed 
only for the primary outcome of the review. This 
was done to provide an overall effect of LNS (re-
gardless of type) over undernutrition compared 
with control or CSB.
The heterogeneity among studies was initially as-
sessed by a visual inspection of forest plots to eval-
uate whether confi dence intervals overlapped. Sta-
tistically, heterogeneity in each meta-analysis was 
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assessed by using the Tau2, I2 and Q statistics. The 
null hypothesis of homogeneity was rejected if P < 
0.1, as the power of this test is low (Higgins and 
Green, 2011). I2 values of 30% to 50% were con-
sidered as moderate to high heterogeneity. Analy-
sis with I2 ≥ 50% signifi ed a great deal of heteroge-
neity, which was explored by using pre-specifi ed 
subgroup analysis and sensitivity analysis.
A subgroup analysis was intended to be performed 
to compare the effects of LNS across the following 
subgroups:
LNS for < 6 months versus for ≥ 6 months—to 
determine whether a longer duration of inter-
vention was more effective than a shorter du-
ration.
Children aged 6 months to 24 months (this time 
is when weaning takes place) versus children 
aged 25 months to 60 months (time when the 
diet is more diverse).
Further, sensitivity analysis was performed while 
omitting every single study, one by one, in succes-
sive steps, to evaluate the infl uence of each study 
on the pooled effect size, in the context of signifi -
cant heterogeneity, by applying the “metainf” com-
mand in STATA. In addition, a sensitivity analysis 
was performed with the exclusion of studies with 
small sample size and with allocation concealment 
bias to explore the infl uence of quality of the stud-
ies on results. The study design was also used as 
a marker for the source of heterogeneity (clus-
ter-randomised trials versus single randomised tri-
als versus quasi-experimental trials).
For primary outcomes and for each intervention 
with 10 or more included studies in the meta-anal-
ysis, putative publication bias was planned to be 
assessed by funnel plot charts of pooled effect 
size standard error (SE). The funnel plot was vi-
sually assessed for sources of asymmetry, such as 
small study effects, publication bias or other. If it 
was likely that the asymmetry was caused by small 
study effects, sensitivity analysis was conducted to 
explore how this affected the results and the con-
clusion of the meta-analysis. Analysis of publication 
bias was assessed by the funnel plot and Egger´s 
test (p-value <0.1 indicated signifi cant asymmetry) 
(Egger et al., 1997).
RESULTS
The summary of the result of the search is pro-
vided in the PRISMA fl ow chart (Figure 1 in on-
line supplementary material). In total, 2061 papers 
were screened, and 18 studies were included in 
this review with 15,876 children.
The characteristics of included studies are pre-
sented in Table 1. Eleven studies were performed 
in Malawi (Lin et al., 2008; Mangani et al., 2013; 
Matilsky et al., 2009; LaGrone et al., 2011; Thakwal-
akwa et al., 2010; Phuka et al., 2009; Phuka et al., 
2008; Phuka et al., 2012; Phuka et al., 2009; Thak-
walakwa et al., 2012; Maleta et al., 2004), two in 
the Democratic Republic of Congo (Bisimwa et al., 
2012; van der Kam et al., 2012) and one each in 
Niger Republic (Isanaka et al., 2009); Sudan (Talley 
et al., 2012), Chad (Huybregts et al., 2012), Ethio-
pia (Karakochuk et al., 2012) and Haiti (Iannotti 
et al., 2014). Seventeen were RCT (including three 
cluster RCT [Isanaka et al., 2009; Huybregts et al., 
2012; Karakochuk et al., 2012]), and one was a qua-
si-experimental trial (Talley et al., 2012). The staple 
foods used in the studies were made from blended 
corn or maize and are also known as Likuni Pha-
la or Improved Dry Ration. The characteristics of 
excluded studies and ongoing studies are present-
ed in Tables 1 and 2, respectively, in supplementary 
online material.
Risk of bias of included studies.
Randomisation was applied in 16 out of 18 studies, 
of which 11 studies had adequate randomisation of 
study participants with a low risk of bias, 6 had an 
unclear randomisation sequence and only one study 
had inadequate randomisation sequence. Blind as-
sessment of outcomes by investigators was done in 
11 studies (Figure 2 supplementary online material). 
The three studies with cluster RCT (Isanaka et al., 
2009; Huybregts et al., 2012; Karakochuk
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Forest plot for the comparison of LNS (milk-based) versus CSB for the mean change in WHZ outcome according to study duration.
The shaded squares represent the sample size, and solid horizontal lines represent the 95% confidence interval (CI).
The diamond represents the pooled WHZ difference, and the solid vertical line represents the null hypothesis of no
effect of LNS. Subgroup analysis according to the study duration (short-term < 6 months vs long-term ≥ 6 months).
Funnel for WHZ outcome for milk-based LNS versus CSB.
SMD, standardized mean difference; SE, standard error
The vertical solid line represents the pooled estimate (WMD), and the diagonal dashed lines represent the pseudo 95%CI around the 
pooled estimate. The WMD of zero indicates no effect. Each circle represents a long-term study, and each triangle is a short-term study.
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Effects of interventions
The summary of pooled estimates of all outcomes 
for all 5 comparison groups is presented in Table 
2. We were unable to analyse results by different 
age groups for all outcomes. There was no explic-
it measuring of allergic reactions as an adverse
outcome.
Comparison group 1: LNS versus
control
Seven trials contributed data for this group.
The majority (n=4) of the trials did not spec-
ify whether LNS was milk- or soy-based. Two
trials (Thakawalakwa et al., 2010; Thakwalakwa
et al., 2012) applied milk-based LNS. One
trial (Mangani et al., 2013) applied both LNS 
milk- and soy-based versus control. In this
situation, we combined data from both milk- and 
soy-based arms and compared with control.
Primary outcomes
There was no effect of LNS on HAZ (WMD= 
-0.01; 95% CI= -0.07, 0.05; n=3046; I2= 25%) com-
pared with those in the control group. Subgroup 
analysis by study duration presented similar re-
sults. Long-term studies (≥ 6 months) were quite 
homogeneous (I2= 0%; P = 0.62) compared with 
short-term studies (I2= 63%; P = 0.04). Hetero-
geneity seemed to be driven by one cluster-ran-
domised study (Huybregts et al., 2012).
The pooled estimate showed that there was a 
tendency to a higher increase in WAZ in the LNS 
group (WMD= 0.29; 95% CI = -0.03, 0.62; n=1240) 
compared with the control group, but the result 
was not statistically signifi cant (P= 0.08) and pre-
sented high heterogeneity (Chi2=26.71, df =3, 
P< 0.00001, I2= 89%). Exclusion of a small study 
(Thakwalakwa et al., 2010) as well as cluster RCT 
(Iannotti et al., 2014) did not reduce heterogeneity. 
Heterogeneity was partially explained by subgroup 
analysis, as long-term studies were homogeneous 
(I2= 0%). Results with shorter administration of 
LNS were statistically signifi cant (WMD= 0.55; 
95% CI= 0.17, 0.93; n=315; I2= 76%). It was not 
possible to perform subgroup analysis based on 
the age of participants as all the children in the 
trials were younger than 2 years.
There was a signifi cant increase in WHZ in the LNS 
group compared with the control group (WMD 
= 0.13; 95% CI= 0.05, 0.22; n= 2752; P= 0.002) 
with no signifi cant heterogeneity (Chi2=5.02; df= 
4; P=0.29; I2=17%). Subgroup analysis showed 
no signifi cant difference between long-term and 
short-term studies (WMD = 0.09 versus WMD = 
0.25; P= 0.09 [for subgroup difference]). None of 
the studies considered recovery from MAM, and, 
therefore, no analysis was performed.
Secondary outcomes
There was a signifi cant higher weight gain (WDM 
= 0.12 kg, 95%CI= 0.05, 0.18; P= 0.0004) among 
those in the LNS group compared with those in 
the control group. Children in the LNS group were 
signifi cantly less likely to have fever and cough com-
pared with those in the control group (p<0.05). 
There was a tendency toward less events of diar-
rhoea among the LNS group compared with the 
control group, but the p-value was borderline (P= 
0.07). There was no signifi cant effect on increase in 
height and MUAC. All subgroup analyses showed 
no signifi cant differences on effect sizes between 
long-term and short-term studies. No signifi cant 
heterogeneity was found in all outcomes, except 
for MUAC (I2 = 55%). However, it was not possible 
to conduct a subgroup analysis based on the du-
ration of intervention as all the trials were short-
term and all the children in the 3 included studies 
were between 6 months and 24 months.
Comparison group 2: LNS (milk-based) 
versus CSB
Primary outcomes
There was a non-signifi cant increase in HAZ among 
children in the LNS group compared with those in 
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the CSB group (WMD=0.02; 95% CI= -0.01, 0.05; 
n=2410; P= 0.24). However, the magnitude of the 
intervention tended to be higher in long-term trials 
(WMD = 0.11; 95% CI = 0.0, 0.21; n = 915; P = 0.04) 
compared with short-term trials (WMD = 0.01; 
95% CI = -0.002, 0.04; n = 1495; P = 0.53).
Children in the LNS group tended to have a high-
er increase in WAZ compared with those in the 
CSB group (WMD = 0.04; 95%CI = -0.001, 0.08; 
n = 1498), but the increase was borderline signif-
icant (P = 0.06). Included studies were homoge-
neous, and subgroup analysis showed no signifi cant 
difference between long-term and short-term 
studies (P for subgroup difference = 0.51).
There was a non-signifi cant increase in WHZ in chil-
dren in the LNS group compared with those in the 
CSB group. Results showed signifi cant heterogene-
ity among trials (Chi2= 247.51, df 10; P < 0.00001; 
I2 = 96%). Subgroup analysis according to interven-
tion duration did not yield statistically signifi cant 
results; however, short-term trials appeared to have 
a higher increase than longer term trials (WMD= 
0.24; 95%CI = -0.02, 0.49 versus WMD =0.01; 95% 
CI = -0.13, 0.15), (Figure1) but the test for subgroup 
difference was not statistically signifi cant (P = 0.13). 
Subgroup analysis based on children’s ages (6 – 24 
months versus > 24 months) did not reduce hetero-
geneity (I2 = 96%). Similarly, sensitivity analysis ex-
cluding the smallest study (Maleta et al., 2004) and 
quasi-experimental study (Talley et al., 2012) did not 
reduce heterogeneity.
Children who received LNS (milk-based) were more 
likely to recover from MAM compared with those 
who received CSB (RR = 1.68; 95%CI = 1.17, 2.39; n= 
3701, P= 0.005), and there was no signifi cant het-
erogeneity detected among trials (Chi2 = 196, df = 3; 
P < 0.00001, I2 = 98%). Subgroup analysis was not 
performed as all trials were short-term and all trials 
included children up to 6 months of age or older.
Secondary outcomes
Children who received LNS (milk-based) had a 
signifi cant higher weight gain (WMD = 0.09 kg; 
95%CI = 0.04, 0.13; P = 0.0001) and higher gain 
in MUAC (WMD = 0.14 cm; 95%CI = 0.02, 0.25; 
P = 0.02) compared with those fed with CSB. 
There was a non-signifi cant increase in height and 
improvement in fever and cough. There was no sig-
nifi cant effect on diarrhoea events among partici-
pants. No signifi cant heterogeneity was found for 
all outcomes, except for height (I2 = 34%; P = 0.08). 
Subgroup analysis showed that children who had 
LNS for a longer time tend to gain more weight 
and height compared with those who had LNS for 
less than 6 months; however, the subgroup differ-
ences were borderline signifi cant.
Comparison group 3: LNS (soy-based) 
versus CSB
Primary outcomes
There was no signifi cant increase in HAZ 
(WMD = 0.04; 95%CI = -0.04, 0.11; n = 2887; 
P = 0.33), WAZ (WMD = 0.03; 95%CI = -0.05, 0.11; 
n = 1989; P = 0.52) and WHZ (WMD = 0.07; 95% 
CI = 0.02, 0.11]; n = 4441; P = 0.007) among chil-
dren in the LNS (soy-based) group compared with 
those in the CSB group. No signifi cant heterogene-
ity was detected among trials.
For WAZ, it was not possible to conduct sub-
group analyses regarding the duration of inter-
vention and children’s age as all trials were less 
than 6 months duration and included children be-
tween 6 and 24 months. The magnitude of the in-
tervention tended to be higher in short-term tri-
als for WHZ and HAZ compared with long-term 
trials, but the difference between groups was not 
statistically signifi cant (P for subgroup difference 
> 0.05).
There was no signifi cant improvement in recovery 
from MAM recovery (RR = 1.06; 95%CI = 0.97, 1.15; 
n = 2691; P = 0.18). A signifi cant heterogeneity was 
found (Chi2 = 4.02; df = 1; P = 0.05; I2 = 75%). Only 
two short-term studies contributed data for this 
outcome. Therefore, subgroup analysis was not 
performed.
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Secondary outcomes
LNS (soy-based) had no signifi cant effect on weight 
gain, gain in height and MUAC and it did not sig-
nifi cantly decrease the risk of fever, cough and di-
arrhoea compared with CSB. Analysis showed no 
signifi cant heterogeneity among all the outcomes 
apart from weight gain (I2= 60%). Subgroup anal-
ysis for weight gain was not performed as all 3 in-
cluded trials were long-term. All studies included 
children between 6 and 24 months; hence, sub-
group analysis was not performed based on age 
for none of the secondary outcomes.
Comparison group 4: LNS (milk-based) 
versus LNS (soy-based)
Primary outcomes
There was no signifi cant difference in HAZ among 
children in the milk-based group compared with 
those in the soy-based group (WMD= -0.04; 
95%CI= -0.12, 0.03; n= 3131). Although results for 
short-term trials tended to favour the soy-based 
group (P= 0.02), subgroup differences between 
short-term (WMD= -0.07; 95%CI= -0.13, -0.01; n 
=2709) and long-term trials (WMD= 0.05; 95%CI= 
-0.09, 0.19; n = 422) were not statistically signifi cant.
A non-statistically signifi cant increase in WAZ 
was found among children (Mangani et al., 2013) 
who had milk-based LNS compared with soy-
based (WMD= 0.04; 95%CI=-0.12,0.20; n= 422, 
P=0.63).
There was no signifi cant difference in WHZ 
among children in the milk-based group compared 
with those in the soy-based group (WMD= 0.02; 
95%CI= -0.11, 0.15; n= 3131; P= 0.79), with signifi -
cant heterogeneity (Chi2= 8.20; df= 2; P= 0.02; I2= 
76%). Subgroup analysis by duration of the inter-
vention did not explain the heterogeneity.
There was no difference between milk-based and 
soy-based groups regarding recovery from MAM 
(RR=1.00; 95%CI= 0.97, 1.03; n= 2739; P=0.98), 
with no heterogeneity among two included trials 
(I2= 0%). Both trials were short-term, and sub-
group analysis was not applicable.
Secondary outcomes
There was no signifi cant difference between milk-
based and soy-based groups regarding all sec-
ondary outcomes. Subgroup analysis and test for 
heterogeneity were not applicable as only single 
studies considered the aforementioned as out-
comes.
Comparison group 5: LNS (milk- or soy-
based) versus Control and/or CSB
Analyses for this comparison group were per-
formed for primary outcomes only.
Overall, children receiving LNS had a non-signifi -
cant increase in HAZ (WMD=0.00; 95%CI= -0.02, 
0.03; I2 = 0%) compared with control and/or CSB. 
Children receiving LNS had a signifi cant increase in 
WAZ (WMD=0.09; 95%CI= 0.02, 0.15; I2 = 52%) 
and WHZ (WMD=0.14; 95%CI= 0.01, 0.26; I2 = 
93%) and were more likely to recover from MAM 
(RR=1.37; 95%CI= 1.14,1.65; I2 = 97%) compared 
with those receiving control and/or CSB (See Sup-
plementary online material Figure 4).
Publication bias
Publication bias was assessed in only one primary 
outcome (WHZ) in LNS (milk-based) versus the 
CSB comparison group, which had 11 included 
studies in the analysis. Figure 2 shows that the fun-
nel plot was asymmetric, indicating the presence 
of publication bias. We further assessed publi-
cation bias by using Egger’s test and found a sig-
nifi cant p-value (0.019) for the presence of small 
study effect. Similar results were observed for the 
LNS (milk- or soy-based) versus Control and/or 
CSB comparison group (LAZ, n = 19 studies, P = 
0.10; WHZ, n= 20 studies, P = 0.103; WAZ, n = 
15 studies, P = 0.03). Since only six studies were 
included for recovery from MAM, analysis was not 
performed.
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DISCUSSION
The aim of this review was to explore the
impact of LNS in normal to moderately malnour-
ished children on HAZ, WAZ, WHZ and recovery 
from MAM. Eighteen studies were found eligible, 
of which seventeen were RCTs (including three 
cluster RCTs) and one was a quasi-experimental 
study.
The main fi ndings show that children receiving 
LNS tend to have better results for most prima-
ry and secondary outcomes compared with those 
having their habitual diet (Control) or receiving 
CSB, although not all the results were statisti-
cally signifi cant. In addition, improved recovery 
from MAM was observed in LNS (milk-based)
compared with CSB (P < 0.05). However, no
signifi cant difference in recovery from MAM was 
seen in the soy-based LNS compared with CSB. 
It is important to consider that only two trials 
contributed data for this particular comparison 
(soy-based LNS versus CSB). The pooled esti-
mate of effect of LNS compared with control or 
CSB (Table1) revealed a statistically signifi cant in-
crease in WAZ, WHZ and recovery from MAM.
However, no effect was seen in HAZ. It is
important to consider that the duration of some 
studies could have been too short for LNS to have 
a signifi cant effect on HAZ.
Quality of evidence
Most of the trials had moderate quality, and only 
two studies required contact with trial authors to 
clarify unclear methodological aspects of which
responses were not received. Seventeen out of 18 
studies reviewed were RCTs, which have a higher 
quality than any other type of study design (Moher 
et al., 2009). However, three of these trials were 
cluster RCTs that were prone to selection bias. 
Overall, the risk of bias was found to be high for 
detection, attrition, performance and other bias-
es, which could have led to overestimation of the
effects of intervention.
Overall completeness and applicability 
of evidence
This systematic review researches the best evi-
dence on the effectiveness of LNS to prevent un-
dernutrition in childhood. We assessed whether 
LNS was more effective than having no supple-
ments or a CSB meal. More importantly, it was 
paramount to know whether the milk-based LNS 
yielded a better outcome than the soy-based LNS 
when compared with CSB. The cost of these prod-
ucts can dictate which of them will be used con-
sistently to tackle undernutrition since the price 
of milk-based LNS is twice that of soy-based LNS 
(Matilsky et al., 2009). Also, the target of the WHO 
to achieve a 40% reduction of less than 5 stunt-
ed children and to reduce childhood wasting to 
less than 5% by the year 2025 (WHO 2015) may 
not be met without completely exhausting the po-
tential of LNS. Further, the fi rst 1000 days of life 
and up to 5 years is a very crucial period where 
nutritional interventions have major contributions 
towards children’s health (UNICEF, WHO, Group 
WB, 2015). This intervention can supply essential 
nutrients that are optimal for preventing under-
nutrition.
Despite many studies having been carried out on 
LNS, most of them focussed on the use of RUTF 
for treatment of SAM and, because of the elicited 
comparison groups, they were not eligible for this 
review. A previous Cochrane review on treatment 
of SAM with RUTF, including only four trials (three 
having a high risk of bias and one trial including 
children infected with human immunodefi ciency 
virus [HIV]), all conducted in Malawi with the same 
contact author, did not reach any defi nitive conclu-
sion on whether home-based RUTF (soy-based) 
was better than the standard type (Nutributter 
containing Milk) (Schoonees A et al., 2013). The 
result of our current review regarding the effect 
of LNS on recovery from MAM is, however, consis-
tent with a meta-analysis by Lenters et al., 2013, in 
which RUSF yielded better recovery than CSB for 
treatment of MAM.
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This review has several limitations. Eleven of the 18 
included studies were conducted in Malawi, where 
the staple diet is corn, which makes it less possible 
to generalise our fi ndings to other countries where 
staple food is different. External validity limitation 
is also prominent as the studies explored the effect 
of LNS on children in a similar age range (6–18 
months), and a few studies included children from 
6 months up 60 months. Only Maleta et al. (2004) 
conducted a trial among older children solely (42 
to 60 months). Therefore, it was not possible to 
compare the effect of LNS between younger and 
older children. Further, only Maleta et al. (2004) had 
information on total daily dietary intake per group. 
There was no detailed information on probability 
of sharing the LNS supplement with other children 
in the household or family members and measures 
to prevent that from occurring. Compliance was 
measured through checking the level of paste in 
jars, sachet counting and caretaker interviews, 
which does not guarantee that the supplements 
were taken by the intended study participant.
As children were exposed to peanuts, soy and milk 
occurrence of allergy would be an important ad-
verse effect of the intervention. However, only two 
studies (Thakwalakwa et al., 2010; Thakwalakwa 
et al., 2012) explored the possibilities of peanut 
allergies and no study tested for soy and milk aller-
gies. LNS have low moisture content, which makes 
them less able to cause diarrhoea; however, very 
few studies explored diarrhoea as an outcome, 
even though diarrhoea is a main cause of child-
hood mortality (UNICEF, 2013). In addition, only 
one study (Phuka et al., 2009a) monitored post-in-
tervention effects of LNS on growth for more 
than 12 months, limiting the possibility to draw 
conclusions for sustained effect of LNS on growth. 
Therefore, further prospective cohort studies may 
be needed to measure effects on growth through 
assessment of expected cognitive developments 
for age and anthropometric measures after a few 
years on supplementation with LNS.
We had limited response from authors and organ-
isations, which could have affected the number of 
studies included in this review. There were limited 
data on recovery from MAM as well as secondary 
outcomes such as MUAC, events of fever, cough 
and diarrhoea. Though some studies are of good 
quality, some bias is commonly present, which may 
compromise results. Only published studies were 
added and, as such, unpublished articles may have 
been missed. Another limitation is that only trials 
published in English were included, with most of 
them being conducted in Africa (Malawi) by the 
same authors. Further, all identifi ed studies con-
ducted in Asia, a continent with a high rate of mal-
nutrition (UNICEF, 2013) focussed on treatment of 
SAM. Hence, these Asian studies were not included 
in the review. Publication bias could not be fully 
assessed for all comparison groups and outcomes 
because of the limited number of included studies. 
For comparison 2 (WHZ), the funnel plot (Figure 
2) shows evidence of asymmetry, indicating publi-
cation bias. However, the asymmetry of the funnel 
plot might also be due to heterogeneity, method-
ological quality and chance. When heterogeneity is 
presented, as observed in this particular outcome 
(I2= 96%), the funnel plot is considered inade-
quate and trim-and-fi ll analysis is usually poorly 
performed. When the analysis was performed by 
using all trials (comparison 5), the level of hetero-
geneity was slightly reduced (I2= 93%) and Egger 
test showed a borderline p-value for small study 
effect (p=0.103) (data not shown). Therefore, our 
fi ndings need to be interpreted with caution.
Implications for practice & research
Given the evidence from the pooled estimates, 
LNS tend to have a slightly better clinical outcome 
on nutritional status compared with CSB and con-
trol. However, other studies on feasibility, accept-
ability, cost effectiveness and long-term effects are 
needed before LNS can be routinely administered 
in developing countries that are prone to malnutri-
tion. The meta-analysis of the few studies with data 
on diarrhoea found that LNS did not signifi cantly 
lower the risk of diarrhoea in children compared 
with CSB, but it tended to reduce the risk of diar-
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rhoea when compared with control (P > 0.05). In 
addition, LNS signifi cantly reduced the risk of fever 
and cough compared with control.
Adequately designed randomised controlled trials 
according to CONSORT guidelines (Consolidated 
standards of reporting trials) on LNS on nutrition-
al outcomes are needed in Asia, with focus also 
on diarrhoea and allergies to peanut, milk and soy-
bean. Since it is not possible to deduce conclusive-
ly that milk-based LNS are better than soy-based 
LNS, further research is needed to ascertain which 
product yield is more effective. To properly elicit 
whether outcome results are dependent on du-
ration of intervention, studies that compare short 
and long durations of interventions are still need-
ed. Future research should also compare interven-
tions between younger and older children.
CONCLUSION
The overall results show that LNS showed sig-
nifi cant improvement on wasting (WHZ), under-
weight (WAZ) and recovery from moderate acute 
malnutrition, although the effect on stunting (HAZ) 
was insignifi cant. Hence, these small differences in 
stunting found make it slightly diffi cult to recom-
mend this intervention at scale. Results of this re-
view might not be applicable to other regions of 
the world with a non-corn-based staple diet. Firm 
conclusions could not be drawn on whether milk-
based LNS were more effective than soy-based 
LNS due to the limited number of included trials 
that used soy-based LNS. Similarly, it is not certain 
whether duration of the intervention and age at 
beginning of the intervention are factors that can 
determine the effect size of the LNS supplemen-
tation until more trials directly addressing these 
issues are carried out. Future research should also 
focus on other contexts and other outcomes (cost 
effectiveness, long-term, relapse, recovery rates 
and death rates) as well as make a comparison 
with other interventions.
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